Future perspectives for insulinotropic agents in the treatment of type 2 diabetes–DPP‐4 inhibitors and sulphonylureas

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Diabetes, obesity and metabolism

• Publication date

  2010-01-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/j.1463-1326.2009.01095.xPMID 19788431
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Medikamentöse antihyperglykämische Therapie des Diabetes mellitus Typ2 Update der Evidenzbasierten Leitlinie der Deutschen Diabetes-Gesellschaft Pharmacological Antihyperglycemic Therapy of Type2 Diabetes mellitus Update of the Evidence-Based Guidelines of the German Diabetes Association

  2009cited by this paper
• Drug evaluation: Vildagliptin-metformin single-tablet combination

  2009cited by this paper
• Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetes.

  2009cited by this paper
• Overview of the Gliptin Class (Dipeptidyl Peptidase-4 Inhibitors) in Clinical Practice

  2009cited by this paper
• Medikamentöse antihyperglykämische Therapie des Diabetes mellitus Typ 2

  2009cited by this paper
• Effects of Intensive Glucose Lowering in Type 2 Diabetes

  2009cited by this paper
• Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy

  2009cited by this paper
• Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis

  2008cited by this paper
• Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes

  2008cited by this paper
• DPP-4 inhibitor therapy: new directions in the treatment of type 2 diabetes.

  2008cited by this paper
• Evaluation of pharmacokinetic and pharmacodynamic interaction between the dipeptidyl peptidase IV inhibitor vildagliptin, glyburide and pioglitazone in patients with Type 2 diabetes.

  2008cited by this paper
• Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial.

  2008cited by this paper
• Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.

  2008cited by this paper
• Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes *

  2008cited by this paper
• Incretin-based therapies in type 2 diabetes: a review of clinical results.

  2008cited by this paper
• Dipeptidyl peptidase-4 as a new target of action for type 2 diabetes mellitus: a systematic review.

  2008cited by this paper
• Effect of Sitagliptin, a Dipeptidyl Peptidase‐4 Inhibitor, on Blood Pressure in Nondiabetic Patients With Mild to Moderate Hypertension

  2008cited by this paper
• The islet enhancer vildagliptin: mechanisms of improved glucose metabolism

  2008cited by this paper
• Is the Combination of Sulfonylureas and Metformin Associated With an Increased Risk of Cardiovascular Disease or All-Cause Mortality?

  2008cited by this paper
• Hypoglycaemia in Type 2 diabetes

  2008cited by this paper
• Emerging dipeptidyl peptidase-4 inhibitors for the treatment of diabetes.

  2008cited by this paper
• Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency

  2008cited by this paper
• Effects of intensive glucose lowering in type 2 diabetes.

  2008cited by this paper
• DPP-4 inhibition improves glucose tolerance and increases insulin and GLP-1 responses to gastric glucose in association with normalized islet topography in mice with beta-cell-specific overexpression of human islet amyloid polypeptide.

  2007cited by this paper
• Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes

  2007cited by this paper
• Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis.

  2007cited by this paper
• Efficacy and tolerability of vildagliptin monotherapy in drug-naïve patients with type 2 diabetes.

  2007cited by this paper
• Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin

  2007cited by this paper
• beta-cell failure in diabetes and preservation by clinical treatment.

  2007cited by this paper
• Bodyweight Changes Associated with Antihyperglycaemic Agents in Type 2 Diabetes Mellitus

  2007cited by this paper
• Sitagliptin: profile of a novel DPP-4 inhibitor for the treatment of type 2 diabetes (update).

  2007cited by this paper
• Vildagliptin in Drug-naïve Patients with Type 2 Diabetes: A 24-Week, Double-blind, Randomized, Placebo-controlled, Multiple-dose Study

  2007cited by this paper
• Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes

  2007cited by this paper
• Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double‐blind, non‐inferiority trial

  2007cited by this paper
• Sitagliptin: Profile of a novel DPP-4 inhibitor for the treatment of type 2 diabetes.

  2007influential reference
• Comparison of Vildagliptin and Rosiglitazone Monotherapy in Patients With Type 2 Diabetes

  2007cited by this paper
• Comparison between vildagliptin and metformin to sustain reductions in HbA1c over 1 year in drug‐naïve patients with Type 2 diabetes

  2007cited by this paper
• Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo‐controlled study *

  2007cited by this paper
• Optimizing combination treatment in the management of type 2 diabetes

  2007cited by this paper
• Meglitinide analogues: a review of clinical data focused on recent trials.

  2006cited by this paper
• Screen-detected diabetes, hypertension and hypercholesterolemia as predictors of cardiovascular mortality in five populations of Asian origin: the DECODA study

  2006cited by this paper
• Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes.

  2006cited by this paper
• Peptide YY(1-36) and Peptide YY(3-36): Part I. Distribution, Release and Actions

  2006cited by this paper
• Three‐year mortality in diabetic patients treated with different combinations of insulin secretagogues and metformin

  2006cited by this paper
• Diabetes and obesity: the twin epidemics

  2006cited by this paper
• Islet beta cell failure in type 2 diabetes.

  2006cited by this paper
• Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy

  2006cited by this paper
• The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.

  2006influential reference
• Efficacy and tolerability of the dipeptidyl peptidase‐4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes

  2006cited by this paper
• Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.

  2006cited by this paper
• Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy

  2006cited by this paper
• Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.

  2006cited by this paper
• Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes.

  2006cited by this paper
• Comparative safety of newer oral antidiabetic drugs

  2006cited by this paper
• Chronic Inhibition of Dipeptidyl Peptidase-4 With a Sitagliptin Analog Preserves Pancreatic β-Cell Mass and Function in a Rodent Model of Type 2 Diabetes

  2006cited by this paper
• Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus

  2006cited by this paper
• Vildagliptin: a novel DPP-4 inhibitor with pancreatic islet enhancement activity for treatment of patients with type 2 diabetes.

  2006influential reference
• Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes.

  2005cited by this paper
• Type 2 diabetes--therapy with dipeptidyl peptidase IV inhibitors.

  2005cited by this paper
• Insulin secretagogues, sulfonylurea receptors and K(ATP) channels.

  2005cited by this paper
• Use of antidiabetic drugs in elderly patients.

  2005cited by this paper
• Improved glycaemic control with dipeptidyl peptidase‐4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response

  2005cited by this paper
• Diabetes in older adults. Overview of AGS guidelines for the treatment of diabetes mellitus in geriatric populations.

  2004cited by this paper
• Inhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of Type 2 diabetes?

  2004cited by this paper
• Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes.

  2004cited by this paper
• Mortality in type 2 diabetic subjects prescribed metformin and sulphonylurea drugs in combination: cohort study

  2004cited by this paper
• Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance

  2003cited by this paper
• Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c).

  2003cited by this paper
• Differential effect of glyburide (glibenclamide) and metformin on QT dispersion: a potential adenosine triphosphate sensitive K+ channel effect.

  2002cited by this paper
• Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European Prospective Investigation of Cancer and Nutrition (EPIC-Norfolk)

  2001cited by this paper
• Effect of repaglinide on cloned beta cell, cardiac and smooth muscle types of ATP-sensitive potassium channels

  2001cited by this paper
• Metabolism of glucagon by dipeptidyl peptidase IV (CD26).

  2001cited by this paper
• Flexible meal-related dosing with repaglinide facilitates glycemic control in therapy-naive type 2 diabetes.

  2001cited by this paper
• Glucose sensing in pancreatic beta-cells: a model for the study of other glucose-regulated cells in gut, pancreas, and hypothalamus.

  2001cited by this paper
• Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria.

  2001cited by this paper
• Dipeptidyl Peptidase IV (DPIV/CD26) Degradation of Glucagon

  2000cited by this paper
• Rapid and short-acting mealtime insulin secretion with nateglinide controls both prandial and mean glycemia.

  2000cited by this paper
• Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

  2000cited by this paper
• Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes.

  2000cited by this paper
• Increased mortality in Type II diabetic patients using sulphonylurea and metformin in combination: a population-based observational study

  2000cited by this paper
• Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes.

  1999cited by this paper
• A comparison of repaglinide and glibenclamide in the treatment of type 2 diabetic patients previously treated with sulphonylureas

  1999cited by this paper
• Repaglinide versus glyburide: a one-year comparison trial.

  1999cited by this paper
• The Use of Sulphonylureas in the Elderly

  1999cited by this paper
• Structural requirements of sulphonylureas and analogues for interaction with sulphonylurea receptor subtypes

  1999cited by this paper
• Dipeptidyl-peptidase IV (CD26)--role in the inactivation of regulatory peptides.

  1999cited by this paper
• Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig.

  1998cited by this paper
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

  1998cited by this paper
• Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)

  1998cited by this paper
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)

  1998cited by this paper
• Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.

  1998cited by this paper
• The absence of a glycemic threshold for the development of long-term complications: the perspective of the Diabetes Control and Complications Trial.

  1996cited by this paper
• Efficacy of insulin and sulfonylurea combination therapy in type II diabetes. A meta-analysis of the randomized placebo-controlled trials.

  1996cited by this paper
• Pharmacokinetic Basis for the Safety of Glimepiride in Risk Groups of NIDDM Patients

  1996cited by this paper
• Long-Term Treatment of Type 2 Diabetic Patients with the New Oral Antidiabetic Agent Glimepiride (Amaryl®): A Double-Blind Comparison with Glibenclamide

  1996cited by this paper
• Problems and Pitfalls of Sulphonylurea Therapy in Older Patients

  1993cited by this paper
• Entero-insular axis and diabetes mellitus.

  1992cited by this paper
• Relationship between lactate dehydrogenase and myeloperoxidase levels in human gingival crevicular fluid and clinical and microbial measurements.

  1988cited by this paper
• 0021-972X/04/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 89(5):2078–2084 Printed in U.S.A. Copyright © 2004 by The Endocrine Society doi: 10.1210/jc.2003-031907 Inhibition of Dipeptidyl Peptidase-4 Reduces Glycemia, Sustains Insulin Levels

  year unknowncited by this paper

• Non-glycemic effects of dipeptidyl peptidase-4 inhibitors: efficacy and safety

  2025cites this paper
• Ameliorative effects of Carica papaya extracts against type II diabetes-induced myocardial pathology and dysfunction in albino rats.

  2021cites this paper
• Glucose-dependent activation, activity, and deactivation of beta cell networks in acute mouse pancreas tissue slices

  2020cites this paper
• Type 2 Diabetes: The Pathologic Basis of Reversible β-Cell Dysfunction

  2016cites this paper
• Intraoral Film Containing Insulin-Phospholipid Microemulsion: Formulation and In Vivo Hypoglycemic Activity Study

  2015cites this paper
• Ipragliflozin: A novel sodium-glucose cotransporter 2 inhibitor developed in Japan.

  2015cites this paper
• Linagliptin: from bench to bedside

  2014cites this paper
• Efficacy and safety of teneligliptin added to glimepiride in Japanese patients with type 2 diabetes mellitus: a randomized, double‐blind, placebo‐controlled study with an open‐label, long‐term extension

  2014cites this paper
• Antidiabetic Actions of an Estrogen Receptor β Selective Agonist

  2013cites this paper
• ffi cacy and Safety of Switching from Basal Insulin to Sitagliptin in Japanese Type 2 Diabetes Patients

  2013cites this paper
• Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data.

  2013cites this paper
• SIRT1 and energy metabolism.

  2013cites this paper
• Antidiabetic actions of an ERβ selective agonist

  2013cites this paper
• Is GPR119 agonism an appropriate treatment modality for the safe amelioration of metabolic diseases?

  2013cites this paper
• Combine and conquer: advantages and disadvantages of fixed‐dose combination therapy

  2013cites this paper
• To Market, To Market—2011

  2012cites this paper
• Pharmacokinetic evaluation of atorvastatin and sitagliptin in combination for the treatment of type 2 diabetes

  2012cites this paper
• Efficacy and Safety of Switching from Basal Insulin to Sitagliptin in Japanese Type 2 Diabetes Patients

  2012cites this paper
• Gemeinsamkeiten und Unterschiede inkretinbasierter Therapien

  2011cites this paper
• What to add in with metformin in type 2 diabetes?

  2011cites this paper
• A New Therapy of Type 2 Diabetes: DPP-4 Inhibitors

  2011cites this paper
• Tratamiento de la hiperglucemia en la diabetes mellitus tipo 2: hacia un tratamiento individualizado

  2011cites this paper
• To Market, To Market—2010

  2011cites this paper
• Hypoglycemia - Causes and Occurrences

  2011cites this paper
• Saxagliptin is non‐inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52‐week randomised controlled trial

  2010cites this paper
• New treatments in the management of type 2 diabetes: a critical appraisal of saxagliptin

  2010cites this paper
• Hypoglykämie und Diabetestherapie – gibt es einen Paradigmenwechsel?

  2010cites this paper
• [DPP-4 inhibitors in clinical use. Therapy without the risk of hypoglycaemia].

  2010cites this paper
• Nutritional intervention in patients with type 2 diabetes who are hyperglycaemic despite optimised drug treatment—Lifestyle Over and Above Drugs in Diabetes (LOADD) study: randomised controlled trial

  2010cites this paper
• DPP-4 inhibitors: what may be the clinical differentiators?

  2010cites this paper
• New treatments in the management of type 2 diabetes: a critical appraisal of saxagliptin

  2010cites this paper
• Drug Profile—Saxagliptin, a Novel Dipeptidyl Peptidase-4 Inhibitor for the Treatment of Type 2 Diabetes

  2009cites this paper
• Linagliptin: from bench to bedside

  year unknowncites this paper